Paul Baskind

640 total citations
25 papers, 513 citations indexed

About

Paul Baskind is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Paul Baskind has authored 25 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 10 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Paul Baskind's work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (6 papers). Paul Baskind is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (6 papers). Paul Baskind collaborates with scholars based in United States and France. Paul Baskind's co-authors include Eric J. Feldman, Tauseef Ahmed, Karen Seiter, Z Arlin, A Mittelman, Carmelo Puccio, Abraham Mittelman, Perry Cook, Arlin Za and Delong Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Paul Baskind

25 papers receiving 497 citations

Peers

Paul Baskind

HEMAT

ONCOL

PHEOH

GENET

P R Taylor United Kingdom

Mohamed Elhamri France

Anna Grazia Recchia Italy

Jan Davisson United States

Kathleen Dugan United States

E. Klumper Netherlands

C. H. Van Zantwijk Netherlands

Jayastu Senapati United States

Y Elisseyeff United States

F. Messa Italy

P R Taylor United Kingdom

Paul Baskind

323 ×0.9

HEMAT

158 ×0.8

137 ×0.8

ONCOL

177 ×1.0

PHEOH

81 ×0.6

GENET

Citations per year, relative to Paul Baskind Paul Baskind (= 1×) peers P R Taylor

Countries citing papers authored by Paul Baskind

Since Specialization

Citations

This map shows the geographic impact of Paul Baskind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Baskind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Baskind more than expected).

Fields of papers citing papers by Paul Baskind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Baskind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Baskind. The network helps show where Paul Baskind may publish in the future.

Co-authorship network of co-authors of Paul Baskind

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Baskind. A scholar is included among the top collaborators of Paul Baskind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Baskind. Paul Baskind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seiter, Karen, et al.. (2018). Acute myeloid leukemia in a father and son with a germline mutation of ASXL1. Biomarker Research. 6(1). 7–7. 10 indexed citations

Seiter, Karen, et al.. (2016). CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. Leukemia Research. 46. 74–78. 3 indexed citations

Seiter, Karen, et al.. (2016). Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. Touro Scholar (Touro College). 3. 27–27. 16 indexed citations

Seiter, Karen, Delong Liu, Eric J. Feldman, et al.. (2006). Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leukemia & lymphoma. 47(3). 425–432. 5 indexed citations

Seiter, Karen, Delong Liu, Thomas P. Loughran, et al.. (2002). Phase I Study of Temozolomide in Relapsed/Refractory Acute Leukemia. Journal of Clinical Oncology. 20(15). 3249–3253. 37 indexed citations

Seiter, Karen, Delong Liu, Eric J. Feldman, et al.. (2001). Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome. Leukemia & lymphoma. 42(5). 963–968. 2 indexed citations

Feldman, Eric J., Karen Seiter, Frank Traganos, et al.. (2000). Phase II Evaluation of a High-Dose Mitoxantrone Based Induction Regimen in Untreated Adults with Acute Myeloid Leukemia. Leukemia & lymphoma. 38(3-4). 309–315. 9 indexed citations

Feldman, E., et al.. (1999). Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion. Bone Marrow Transplantation. 24(10). 1073–1077. 2 indexed citations

Seiter, Karen, H. Dorota Halicka, Frank Traganos, et al.. (1998). In vitro effects and clinical evaluation of a human chorionic gonadotrophin preparation in acute leukemia. Leukemia. 12(11). 1749–1755. 6 indexed citations

10.

Feldman, Eric J., et al.. (1996). Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.. PubMed. 10(1). 40–2. 63 indexed citations

11.

Feldman, Eric J., D S Alberts, Z Arlin, et al.. (1993). Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.. Journal of Clinical Oncology. 11(10). 2002–2009. 49 indexed citations

12.

Kreis, Willi, Martin Lesser, Daniel R. Budman, et al.. (1992). Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemotherapy and Pharmacology. 30(2). 126–130. 17 indexed citations

13.

Feldman, Eric J., Tamjeed Ahmed, A Mittelman, et al.. (1992). Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.. PubMed. 6(11). 1185–8. 44 indexed citations

14.

Arlin, Zalmen A., Eric J. Feldman, Abraham Mittelman, et al.. (1991). Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer. 68(6). 1198–1200. 22 indexed citations

15.

Za, Arlin, Tamer A. Ahmed, A Mittelman, et al.. (1991). Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.. PubMed. 5(8). 712–4. 20 indexed citations

16.

Feldman, Eric J., Tauseef Ahmed, Abraham Mittelman, et al.. (1990). Preliminary Experience with Short Course High-Dose Mitoxantrone in Combination with High-Dose Cytarabine in Patients with Acute Leukemia and Blastic Phase of Chronic Myelogenous Leukemia. Leukemia & lymphoma. 3(3). 209–211. 4 indexed citations

17.

Feldman, Eric J., Zalmen A. Arlin, Tauseef Ahmed, et al.. (1989). Acute Promyelocytic Leukemia: A 5-Year Experience with New Antileukemic Agents and a New Approach to Preventing Fatal Hemorrhage. Acta Haematologica. 82(3). 117–121. 18 indexed citations

18.

Mittelman, Abraham, et al.. (1989). Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers. Journal of Clinical Microbiology. 27(10). 2305–2308. 5 indexed citations

19.

Za, Arlin, Eric J. Feldman, Sanford Kempin, et al.. (1988). Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood. 72(2). 433–435. 49 indexed citations

20.

Arlin, Z, Tauseef Ahmed, A Mittelman, et al.. (1987). A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.. Journal of Clinical Oncology. 5(3). 371–375. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact